Abbott, Blood Centers of America Launch First-of-its-Kind Mixed Reality Experience for Use During Blood Donation

 
 
  • Mixed reality offers donors an innovative, immersive digital experience while giving blood
  •  
  • The Abbott technology is one of the first-ever, consumer-focused mixed reality applications completely controlled through eye tracking
  •  
  • Innovation aims to improve the experience and attract new, younger blood donors by adding an element of high-tech mixed reality
  •  

Abbott (NYSE: ABT) and Blood Centers of America are unveiling an innovative new mixed reality experience for use during blood donation.

 
 

  Abbott and Blood Centers of America are launching a first-of-its-kind mixed reality experience for use during blood donation. 

 
 

The mixed reality technology is an immersive digital experience designed to improve the blood donation process, attract new donors and motivate a younger generation to give blood. The effort intends to address the global challenge of sustaining a reliable blood supply.

 

"This innovative use of mixed reality is the most recent example of how Abbott is creating leading-edge technology to address a key health care need in the world – maintaining the blood supply," said Alex Carterson, divisional vice president, medical, scientific and clinical affairs, Abbott. "Not only is it an immersive and unique use of mixed reality controlled completely through eye tracking, it's a high-tech and creative way to improve the donation experience and make it more appealing for people to participate."

 

The mixed reality experience allows blood donation professionals to safely conduct the donation and interact with donors at every step of the process. Donors' eyes are always visible during donation to ensure constant monitoring and evaluation. Participants wear lightweight mixed reality headsets to enter a digital world but remain fully aware of their surroundings, ensuring a seamless, convenient and safe donation.

 

Abbott, a global leader in screening blood and plasma, is partnering with Blood Centers of America, the largest blood supplier network in the U.S., to introduce this new technology which was first showcased during CES (the Consumer Electronics Show) in Las Vegas .

 

The mixed reality experience was designed based on research that natural settings are the most preferred environment as donors give blood. Participants visit a whimsical garden while listening to soothing music, planting seeds that grow into colorful trees and flowers.

 

The experience is currently being piloted on a limited basis at select Blood Centers of America locations nationwide.

 

One of the biggest challenges facing the sustainability of our nation's blood supply over the last decade is the loss of a significant portion of donors under the age of 30. On average only 3% of the U.S. population donates blood each year, and a recent poll of U.S. adults showed that only 15% of 18-to-34-year-olds donated blood in 2020.

 

"We're always looking for ways to cultivate the next generation of blood donors and find younger people interested in giving," said Harpreet K. Sandhu , CEO, Stanford Blood Center ( Palo Alto, Calif. ) and chairperson of Blood Centers of America. "Some people are hesitant to donate for a variety of reasons or just don't think about giving blood. Since the need for blood is constant, we're continually looking for smart new ways that will appeal to people who have never donated before or may be apprehensive. The mixed reality experience is a terrific way to get those people interested in participating. It adds a fun, interactive element to donation and it's easy and convenient for blood centers to use."

 

Mixed reality is similar to virtual reality but allows users to see the real world around them as they immerse themselves in a digital world, whereas in virtual reality, users only experience the digital world. The mixed reality journey uses Microsoft HoloLens 2, the world's first self-contained holographic computer, enabling hands-free interaction with three-dimensional digital objects and a library of applications. Donors are offered a quick tutorial on the headsets and the mixed reality world prior to use. The headsets can be adjusted for each donor's comfort and are easily integrated into the donation process.

 

"At Microsoft, we've seen the impact digital technologies can have in healthcare – from empowering health team collaboration and increasing clinician productivity to enhancing the patient experience," said David C. Rhew , M.D., global chief medical officer and vice president of healthcare, Microsoft. "We're pleased to see Abbott embrace mixed reality to create a positive experience for blood donors and to encourage the public to donate."

 

As part of the effort to launch this new technology, BCA and Abbott are asking people to pledge to donate blood now and sign up to be notified when the mixed reality experience becomes available in their local area. To learn more about becoming a regular donor and pledge to donate, visit bethe1donor.com/CES .

 
  About Abbott  
 

Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medical devices, nutritionals and branded generic medicines. Our 113,000 colleagues serve people in more than 160 countries.

 

Connect with us at    www.abbott.com    , on LinkedIn at    www.linkedin.com/company/abbott-/    , on Facebook at    www.facebook.com/Abbott    and on Twitter @AbbottNews.

 

 

 
 

  Abbott and Blood Centers of America are launching a first-of-its-kind mixed reality experience for use during blood donation. 

 

  Abbott Logo (PRNewsFoto/Abbott) 

 
 

 Cision View original content to download multimedia: https://www.prnewswire.com/news-releases/abbott-blood-centers-of-america-launch-first-of-its-kind-mixed-reality-experience-for-use-during-blood-donation-301714401.html  

 

SOURCE Abbott

 
 

News Provided by PR Newswire via QuoteMedia

ABT
The Conversation (0)
Abbott Announces New Partnerships and Programs to Advance its Diversity in Clinical Trials Initiative

Abbott Announces New Partnerships and Programs to Advance its Diversity in Clinical Trials Initiative

 
 
  • New efforts focus on research infrastructure, continued training of diverse clinical research personnel and improved diversity within Abbott's own clinical trials
  •  
  • Abbott's Diversity in Clinical Trials initiative aligns with the company's continued focus for greater health equity, expanded access, affordability and removing barriers to life-saving technology and innovation
  •  
  • The new programs build on a successful first year of the multi-million-dollar corporate initiative
  •  

Abbott (NYSE: ABT) today announced a series of new programs within its multi-million-dollar initiative to increase diversity in clinical trials and improve care among under-represented populations. The new additions to Abbott's Diversity in Clinical Trials initiative build on the partnerships, scholarships, and the focus on diversified participants in the company's own clinical trials during the initiative's first year.

 

The latest programs include the launch of a new initiative with the Norton Healthcare Foundation to build and implement new models of sustainable clinical research alongside the Institute for Health Equity, a Part of Norton Healthcare in Louisville, Ky. ; a new training program for clinical research coordinators in partnership with Barnett International; and a newly-created Diversity in Research Office at Abbott focused on ensuring diverse representation in clinical trials.

 

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less
richard murray md

Avisa Diagnostics Appoints Dr. Richard Murray as Chief Medical Officer

 

Avisa Diagnostics Inc. (CSE:AVBT) (Avisa), a clinical-stage medical device company developing an ultra-rapid, point-of-care biomarker breath test for the detection and monitoring of virulent bacterial lung infections, is pleased to announce that the Company has hired Richard K. Murray, M.D., to the newly created position of Chief Medical Officer (CMO).

 

Dr. Murray has over 25 years of industry experience. He worked at Merck & Co. for many years in positions of increasing responsibility, in a variety of business, medical and scientific areas. His most recent position was Vice President and Deputy Chief Patient Officer. Dr. Murray was also a Fellow at the Advanced Leadership Initiative at Harvard University. He has managed all areas of medical affairs, including outcomes research, medical information, professional and academic affairs, field-based medical physicians, and investigator-initiated trials globally. Prior to his industry career, he was a practicing physician in cardiovascular-pulmonary medicine and an asthma researcher at the Hospital of the University of Pennsylvania. Dr. Murray has an M.D. from Howard University and an M.A. in Chemistry and A.B. in Psychology from Clark University. Dr. Murray currently is Board Chair of the Asthma and Allergy Foundation of America.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
illustration of brain and cell phone.

BlinkLab Completes First Patient Test for US Autism Diagnostic Study

Digital healthcare company BlinkLab (ASX:BB1) has tested the first patient in its US autism diagnostic study, which is geared at validating the company's Dx1 test as a diagnostic aid for clinicians.

BlinkLab states in its Wednesday (March 12) release that the study is the largest digital diagnostic trial for autism in the US, with its aim being to support the early detection of developmental conditions like autism.

The first patient test took place at PriMED Clinical Research in Dayton, Ohio. PriMED, a division of PriMED Physicians, is one of two clinical sites selected for the study’s initial phase, which is targeting 100 patients.

Keep reading...Show less
HeraMED Signs Strategic Collaboration Agreement with Garmin Health

HeraMED Signs Strategic Collaboration Agreement with Garmin Health

HeraMED Limited (ASX: HMD), a medical data and technology company leading the digital transformation of maternity care, is delighted to announce it has entered into a collaboration agreement with Garmin (NYSE: GRMN), a leading global provider of smartwatches and GPS-enabled products, aimed at enhancing remote pregnancy monitoring and expanding the range of health data available to expectant mothers and their healthcare providers.

Keep reading...Show less
Cardiologist wearing virtual reality glasses.

2 Biggest Medical Device ETFs in 2025

Exchange-traded funds (ETFs) are a popular investment strategy, and generally contain a variety of publicly traded companies under one stock symbol, often with a focus on a specific sector.

Depending on the ETF, investors may be able to track up-and-coming companies, get exposure to top firms or a mix of both. Aside from stocks, some ETFs also track commodities or bonds.

In the healthcare industry, medical device ETFs bring together companies that go to great lengths to develop pharmaceutical-based technology that can improve the lives of patients.

Keep reading...Show less
Cyclomedica

Cyclopharm Signs US Agreement with HCA Healthcare for Technegas®

Cyclopharm Limited (ASX: CYC) is pleased to announce the signing of a major contract with Hospital Corporation of America Healthcare (HCA), one of the largest single healthcare providers in the United States. This agreement marks a significant milestone for the company which will allow the deployment of Technegas® in up to 169 nuclear medicine departments across HCA’s extensive network.1

Keep reading...Show less
CONNEQT App Launches in USA as Pulse Deliveries Commence

CONNEQT App Launches in USA as Pulse Deliveries Commence

Cardiex Limited (CDX:AU) has announced CONNEQT App Launches in USA as Pulse Deliveries Commence

Download the PDF here.

Female doctor with clipboard talking to smiling female patient at hospital.

Revolutionizing Women's Health: Antifungal Innovation Brings New Investment Opportunities

The intersection of women's health and antifungal innovation represents a pivotal moment in healthcare, offering both transformative medical advancements and compelling investment opportunities.

The groundbreaking developments in antifungal treatments specifically targeting women's health issues present a substantial market potential, resulting in rising investor interest in this rapidly evolving sector.

Despite comprising half the global population, women face unique health challenges that have historically received insufficient attention and investment. Among these health challenges, vaginal candidiasis stands out as a persistent and widespread issue affecting millions of women worldwide.

Keep reading...Show less

Latest Press Releases

Related News

×